无内激光玻璃体切除术联合阿柏西普单药治疗增生性糖尿病视网膜病变相关玻璃体积血的并发症、依从性和 3 年结局。
Complications, Compliance, and 3-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage.
出版信息
Ophthalmic Surg Lasers Imaging Retina. 2023 Feb;54(2):89-96. doi: 10.3928/23258160-20221216-02. Epub 2023 Feb 1.
BACKGROUND AND OBJECTIVE
To report the 3-year outcomes for endolaserless vitrectomy with intravitreal aflibercept injection (IAI) monotherapy for proliferative diabetic retinopathy (PDR)-related vitreous hemorrhage (VH).
MATERIALS AND METHOD
Eyes underwent endolaserless vitrectomy and received one preoperative and intraoperative IAI followed by randomization to a q8week or q16week IAI group. Additional IAI was administered as needed.
RESULTS
31/40 eyes were randomized (14 q8week eyes, 17 q16week eyes). Through 152 weeks, q8week and q16week eyes received 18.6 and 12.1 IAI, respectively. Q8week eyes observed a 34 letter visual acuity (VA) increase ( = 0.003) compared to a 27 letter increase in the q16week group ( = 0.013).
CONCLUSIONS
Endolaserless vitrectomy with aflibercept monotherapy for PDR-related VH provides significant long-term visual gains. Frequent IAI is required for fewer proliferative consequences. .
背景与目的
报告增生型糖尿病视网膜病变（PDR）相关玻璃体出血（VH）患者行无内界膜激光玻璃体切除术联合玻璃体内注射阿柏西普（IAI）单药治疗的 3 年结局。
材料与方法
患者行无内界膜激光玻璃体切除术，于术前和术中接受单次 IAI，并随机分为 q8 周 IAI 组或 q16 周 IAI 组，根据需要追加 IAI。
结果
40 只眼中有 31 只（14 只 q8 周眼，17 只 q16 周眼）被随机分配。在 152 周时，q8 周眼和 q16 周眼分别接受了 18.6 和 12.1 次 IAI。q8 周眼的视力（VA）提高了 34 个字母（=0.003），而 q16 周眼的 VA 提高了 27 个字母（=0.013）。
结论
无内界膜激光玻璃体切除术联合阿柏西普单药治疗 PDR 相关 VH 可带来显著的长期视力获益，频繁应用 IAI 可减少增生性并发症。
Zotero 插件